5 results about "Oligodendrocyte differentiation" patented technology

The present disclosure provides the use of ATDR and ATDRA in the treatment of white matter diseases, and in particular provides all trans-13, 14-dihydroretinol (ATDR) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt comprising all trans-13, 14-dihydroretinol (ATDR) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt comprising all trans-13, 14-dihydroretinoic acid (ATDRA) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof. The present invention relates to a composition comprising 1, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, retinol saturase (Retsat) or a variant thereof, a nucleic acid encoding Retsat or a variant thereof, an expression cassette comprising a nucleic acid encoding Retsat or a variant thereof, a vector comprising a nucleic acid encoding Retsat or a variant thereof, and a method for preparing the same. Use of a cell expressing Retsat or a variant thereof for the preparation of a medicament for the prevention and / or treatment of leukoencephalopathy in a subject in need thereof, which promotes oligodendrocyte differentiation and myelination to thereby treat leukoencephalopathy.

The invention relates to the field of biomedical engineering, in particular to a culture system for chemically reprogramming mouse astrocytes into oligodendrocyte precursor cells and a culture method and application of the culture system. The culture system comprises a reprogramming induction first-stage culture medium and a reprogramming induction second-stage culture medium; the culture medium is composed of a basic culture medium, and an induction compound and an induction factor which are combined with the basic culture medium. By using the chemical reprogramming induction culture system with definite chemical components, the oligodendrocyte precursor cells derived from the mouse astrocytes can be rapidly obtained in vitro, and the precursor cells are maintained to be stably self-renewed for at least five generations in vitro; the oligodendroglia precursor cell has a function of further differentiating to the oligodendroglia cell.

A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK / ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK / ERK pathway inhibitor for treating diseases is also disclosed.

The present disclosure provides the use of ATDR and ATDRA in treating white matter diseases, in particular, provides the use of all-trans-13,14-dihydroretinol (ATDR) and / or all-trans-13,14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a composition comprising all-trans-13,14-dihydroretinol (ATDR) and / or all-trans-13,14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, retinol saturase (Retsat) or a variant thereof, a nucleic acid encoding Retsat or a variant thereof, an expression cassette comprising a nucleic acid encoding Retsat or a variant thereof, a vector comprising a nucleic acid encoding Retsat or a variant, a cell expressing Retsat or a variant thereof in the preparation of a medicament for preventing and / or treating white matter diseases in a subject in need thereof, which can promote the differentiation of oligodendrocytes and myelination to treat white matter diseases.

The present application provides a method for directly transdifferentiating spermatogonial stem cells (SSCs) into neural stem cell-like cells (iNSCs). The iNSCs have proliferative activity, can be stably subcultured in vitro, and have the potential to differentiate into other neural cells such as neurons, astrocytes and oligodendrocytes. The method of the present application has high efficiency, can obtain more iNSCs in a relatively short period in vitro, and can obtain iNSCs with high purity, wherein the double positive rate of Nestin and Pax6 is more than 95%.